EMA Semaglutide Approval and What It Actually Means If You Live in the UK

You found a headline about the EMA and semaglutide, here's what that actually means for you

It's an understandable source of confusion. Since Brexit, the UK and the EU have run separate medicines-licensing systems, and coverage of one can easily bleed into the other online. The European Medicines Agency grants marketing authorisations that apply in EU member states. The UK's Medicines and Healthcare products Regulatory Agency (the MHRA) makes its own independent assessments, and its decisions apply here.

When semaglutide for weight management was approved across EU countries, that was an EMA decision. The UK's equivalent came through the MHRA, and the licensed product here is Wegovy. The two processes often reach similar conclusions, but they are separate, and the MHRA's approval is the one that counts when you're talking to a prescriber in England, Scotland, Wales or Northern Ireland.

If you've been reading about EMA approvals and wondering whether semaglutide is available or legal in the UK, it is, under the Wegovy brand, via a UK prescription. The Wegovy treatment overview covers what the MHRA has licensed, the clinical trial evidence behind it, and how a UK prescription works in practice.

What the MHRA has actually approved for semaglutide in the UK

The MHRA's authorisations for semaglutide now cover more ground than many people realise. Wegovy as a once-weekly subcutaneous injection has been licensed for weight management for several years. In January 2026, the MHRA approved a higher 7.2mg maintenance dose for the injection, and on 14 April 2026 it authorised a dedicated single-dose 7.2mg pen (one pre-set weekly injection) for adults with a BMI of 30 or above.

Then, on 11 June 2026, the MHRA granted approval for Wegovy tablets: oral semaglutide co-formulated with an absorption enhancer, making the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. The tablet schedule starts at 1.5mg daily and escalates through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each stage before a prescriber considers moving up.

That's a lot of movement in a short period, and it's one reason searches for semaglutide approvals (EMA or otherwise) are spiking. The semaglutide guide on this site keeps pace with the latest UK-specific position. For the authoritative regulatory record, the MHRA's announcement on the 7.2mg pen approval sets out the exact indication and criteria.

Clinical evidence: what the trials showed and how regulators (EMA and MHRA) used them

Both the EMA and MHRA based their decisions on a shared body of clinical trial data, because Novo Nordisk ran global trials that enrolled participants across multiple countries. The STEP 1 trial, published in the New England Journal of Medicine, is the landmark study most often cited: 68 weeks of treatment with semaglutide 2.4mg produced an average body-weight reduction of around 15% compared with placebo, in adults with obesity or overweight and a weight-related condition, alongside lifestyle support.

For the oral tablet, phase 3 data from the OASIS 4 trial (307 adults, 64 weeks) showed average weight loss of roughly 13.6%, and approximately 17% among participants who adhered fully to the treatment schedule, which is a meaningful distinction worth understanding before you start. If you want to understand what moving through the dose stages involves, our guide to semaglutide 2 walks through the escalation schedule and what to expect at each step.

Regulators on both sides of the Channel reviewed this evidence and reached broadly similar conclusions about benefit versus risk. The practical difference for UK patients is simply that the MHRA's authorisation, not the EMA's, defines what's legally prescribable here. Questions about whether the evidence applies to you personally are exactly what a consultation is for. You can read more about how semaglutide works and the side-effect profile before you decide whether to take that step.

Ozempic, Rybelsus, Wegovy: semaglutide by another name

Semaglutide appears under several brand names, and it's worth being precise, because the licensed indication differs between them. Ozempic is semaglutide in injection form, but it is licensed for type 2 diabetes, not weight management. The MHRA is clear on this, and prescribing it off-label for weight loss is not appropriate when Wegovy exists for that purpose. Rybelsus is oral semaglutide (at 3mg, 7mg and 14mg), also licensed for type 2 diabetes, those tablet strengths are distinct from the Wegovy tablet schedule and should not be confused with it.

If you've seen Ozempic discussed online as a weight-loss option, or found Rybelsus tablets mentioned in the context of obesity treatment, the simple rule is this: Wegovy (injection or tablet) is the semaglutide product licensed in the UK for weight management. A prescriber working within the rules will not issue Ozempic or Rybelsus for weight loss when Wegovy is the appropriate licensed route. Our sema semaglutide page explains how these brand names relate to the same active ingredient and why the distinction between them matters clinically.

For anyone weighing up the differences between GLP-1 options available in the UK right now, the weight-loss treatment overview sets them out side by side. It's also worth knowing that NICE has recommended semaglutide (under reference TA875) for NHS use, though the criteria are strict and access through NHS services typically involves a specialist weight management pathway with waiting times to match. If you want a fuller picture of where semaglutide sits within the broader range of treatment options, the semaglutide 3 page covers the comparisons in more detail.

If you'd like to explore whether semaglutide is appropriate for your circumstances through a private route, our prescribers review consultations the same day, real clinicians, not automated decision trees. Check your eligibility and take it from there.